Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 5/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.33 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.33 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.33 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL3964315 | 0.98 | MAPT (0.36) | MAPTMAPK1LMNAL3MBTL1ALDH1A1 | |
| Acetone SCHEMBL2803668 | 0.97 | MAPT (0.35) | MAPTMAPK1LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL10795559 | 0.89 | MAPT (0.51) | MAPTMAPK1LMNAALDH1A1FAAH | |
| SCHEMBL769533 | 0.88 | MAPT (0.54) | MAPTMAPK1LMNAALDH1A1FAAH | |
| SCHEMBL15262436 | 0.88 | MAPT (0.54) | MAPTMAPK1LMNAALDH1A1FAAH | |
| SCHEMBL19458643 | 0.88 | MAPT (0.54) | MAPTMAPK1LMNAALDH1A1FAAH | |
| SCHEMBL8190440 | 0.88 | MAPT (0.54) | MAPTMAPK1LMNAALDH1A1FAAH | |
| SCHEMBL15463455 | 0.88 | MAPT (0.54) | MAPTMAPK1LMNAALDH1A1FAAH | |
| SCHEMBL2800456 | 0.88 | MAPT (0.54) | MAPTMAPK1LMNAALDH1A1FAAH | |
| SCHEMBL373408 | 0.88 | MAPT (0.54) | MAPTMAPK1LMNAALDH1A1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114317659-B | Preparation method of soybean oligopeptide powder with multiple biological activities | 杭州佳嘉乐生物技术有限公司 | 2024-01-26 | — | — | CN | claimed |
| CN-115590240-A | Preparation method and product of heated cigarette for regulating nicotine slow-release effect | 广东中烟工业有限责任公司（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-114317659-A | Preparation method of soybean oligomeric active peptide powder with multiple biological activities | 杭州佳嘉乐生物技术有限公司 | 2022-04-12 | — | — | CN | claimed |
| US-20250163247-A1 | RESIN COMPOSITION, APPLICATION THEREOF, AND MOLDING METHOD THEREFOR | OSAKA GAS CHEMICALS CO., LTD. (JP) | 2025-05-22 | — | — | US | disclosed |
| CN-118647665-A | Resin composition, use thereof and molding method | 大阪燃气化学有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-20240110192-A1 | BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER | SYNLOGIC OPERATING COMPANY, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-11896627-B2 | Bacteria engineered to treat metabolic diseases | SYNLOGIC OPERATING COMPANY, INC. (US) | 2024-02-13 | — | — | US | disclosed |
| CN-114317659-B | Preparation method of soybean oligopeptide powder with multiple biological activities | 杭州佳嘉乐生物技术有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11845964-B2 | Bacteria engineered to treat diseases associated with hyperammonemia | SYNLOGIC OPERATING COMPANY, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| WO-2023166943-A1 | RESIN COMPOSITION, APPLICATION THEREOF, AND MOLDING METHOD THEREFOR | 大阪ガスケミカル株式会社 | 2023-09-07 | — | — | WO | disclosed |
| US-11685925-B2 | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier | SYNLOGIC OPERATING COMPANY, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20170067065-A1 | BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER | SYNLOGIC, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| EP-3122382-A2 | GLUCOSE ANALOGS FOR DIAGNOSIS OF DISEASE STATES | Technology Innovation Momentum Fund (Israel) Limited Partnership (IL) | 2017-02-01 | — | — | EP | disclosed |
| WO-2016210384-A2 | BACTERIA ENGINEERED TO TREAT METABOLIC DISEASES | SYNLOGIC, INC. (US) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016200614-A2 | BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA | SYNLOGIC, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20160333326-A1 | Bacteria Engineered to Treat Diseases Associated with Hyperammonemia | SYNLOGIC, INC. | 2016-11-17 | — | — | US | disclosed |
| WO-2015145447-A2 | GLUCOSE ANALOGS FOR DIAGNOSIS OF DISEASE STATES | TECHNOLOGY INNOVATION MOMENTUM FUND (ISRAEL) LIMITED PARTNERSHIP (IL) | 2015-10-01 | — | — | WO | disclosed |
| EP-1942869-A2 | CARBOXYALKYL CELLULOSE ESTERS FOR SUSTAINED DELIVERY OF PHARMACEUTICALLY ACTIVE SUBSTANCES | EASTMAN CHEMICAL COMPANY (US) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007056125-A2 | CARBOXYALKYL CELLULOSE ESTERS FOR SUSTAINED DELIVERY OF PHARMACEUTICALLY ACTIVE SUBSTANCES | EASTMAN CHEMICAL COMPANY (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070104787-A1 | Carboxyalkyl cellulose esters for sustained delivery of pharmaceutically active substances | EASTMAN CHEMICAL COMPANY | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845964-B2 | Bacteria engineered to treat diseases associated with hyperammonemia | ASS1, AGXT, OAT | MAPT 1135/4885MAPK1 4430/4885LMNA 4156/4885 |
| US-20160333326-A1 | Bacteria Engineered to Treat Diseases Associated with Hyperammonemia | ASS1, AGXT, OAT | MAPT 1135/4885MAPK1 4430/4885LMNA 4156/4885 |
| US-20240110192-A1 | BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER | FABP2, TLR9, LY96 | MAPT 1969/4885MAPK1 3368/4885LMNA 3923/4885 |
| US-20070104787-A1 | Carboxyalkyl cellulose esters for sustained delivery of pharmaceutically active substances | SLC2A1, SLC2A8, SLC2A4 | MAPT 3571/4885MAPK1 4413/4885LMNA 4523/4885 |
| US-11685925-B2 | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier | FABP2, TLR9, LY96 | MAPT 1969/4885MAPK1 3368/4885LMNA 3923/4885 |
| US-20170067065-A1 | BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER | FABP2, TLR9, LY96 | MAPT 1969/4885MAPK1 3368/4885LMNA 3923/4885 |
| US-11896627-B2 | Bacteria engineered to treat metabolic diseases | GOT2, BPGM, MLYCD | MAPT 1558/4885MAPK1 3889/4885LMNA 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.